PRTA
Prothena Corp Public Ltd Co Health Care Pharmaceutical Preparations Russell 3000
$8.47Close
$456.0MMarket cap
$7.91 – $11.5152-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 30 · weaker than 70% of stocks over 12 months
- Far from its high 26% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
26%
1wk
up 3.3%
price change
1mo
up 1.1%
price change
12-month return
down 19%
market up 11% ·
its own down 31%
F-score
—
— Not assessed
Altman Z
-0.99
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
down 144.6%
EBIT / enterprise value
Cheaper than
27%
of the market · expensive
Revenue growth
down 93%
year on year
EPS growth
—
latest quarter
Sales growth
down 77%
latest quarter · -1784 pts
ROE
down 64%
return on equity
Free cash margin
down 1689%
-$163.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
5.1%
$0.43 a day · 2×ATR $7.61
RS
30 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
1.20
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Revenue shrinking Revenue fell 92.8% over the year, from $135.2M to $9.7M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+3% vs market2 sessions after results
Financials
- Net -2521%
- Free cash -1689%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $853,000 | $200.6M | $53.9M | $91.4M | $135.2M | $9.7M |
| Operating income | -$112.7M | $72.0M | -$131.6M | -$191.0M | -$154.6M | -$214.6M |
| Net income | -$111.1M | $67.0M | -$116.9M | -$147.0M | -$122.3M | -$244.1M |
| Net margin | -13030% | 33% | -217% | -161% | -90% | -2521% |
| Earnings per share | -$2.78 | $1.38 | -$2.47 | -$2.76 | -$2.27 | -$4.53 |
| Free cash flow | -$80.4M | $92.6M | -$108.8M | -$133.9M | -$150.1M | -$163.6M |
| Free cash margin | -9421% | 46% | -202% | -147% | -111% | -1689% |
| Cash | $295.4M | $579.1M | $710.4M | $618.8M | $471.4M | $307.5M |
| Shareholders' equity | $184.0M | $466.0M | $622.0M | $561.4M | $486.9M | $280.5M |
| Shares outstanding | 39.92m | 46.66m | 52.10m | 53.68m | 53.83m | 53.83m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Agreement ended ↗ |
| Oct 2, 2026 | Director or officer change ↗ |
| Aug 6, 2026 | Results ↗ |
| May 15, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 27, 2026 | Regulation FD · Other events ↗ |
| Feb 19, 2026 | Results ↗ |
| Dec 12, 2025 | Director or officer change ↗ |
| Nov 19, 2025 | Shareholder vote ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 27, 2025 | Other events ↗ |
| Aug 6, 2025 | Other events ↗ |